ProCE Banner Activity

A Team Approach to Optimizing TKI Therapy for Patients With Chronic Myeloid Leukemia

Clinical Thought
Review expert insights and recommendations on the evolving management of patients with CML receiving long-term TKI therapy.

Released: November 15, 2019

Expiration: November 13, 2020

No longer available for credit.

Share

Faculty

Jorge Cortes

Jorge Cortes, MD

Professor of Medicine
Deputy Chair, Department of Leukemia
M.D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Faculty Disclosure

Primary Author

Jorge Cortes, MD

Professor of Medicine
Deputy Chair, Department of Leukemia
M.D. Anderson Cancer Center
Houston, Texas

Jorge E. Cortes, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb, Novartis, Pfizer, Sun Pharma, and Takeda and consulting fees from Bristol-Myers Squibb, Novartis, Pfizer, and Takeda.